Drug Trial Radar · NCT07226817
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Dec 17, 2026
Study completion Dec 17, 2026
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.
Conditions
- Healthy Volunteers
Interventions
BMS-986435Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Up to Day 28
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))Time frame: Up to Day 28
- Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Miami
Miami, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.